For decades, scientists believed that insulin release was regulated exclusively by blood glucose levels. This view shifted in the late twentieth century, when researchers demonstrated that the gastrointestinal tract plays an active role in metabolic regulation. These insights ultimately led to the identification of glucagon-like peptide-1 (GLP-1).
In the 1960s, researchers observed that oral administration of glucose triggered a significantly stronger insulin response than intravenous glucose, even when blood glucose concentrations were equivalent. This phenomenon, later termed the incretin effect, indicated that hormones released by the intestine after food intake signal the pancreas to secrete insulin.
In the mid-1980s, GLP-1 was identified as a key gut hormone. After a meal, the intestine releases GLP-1, which:
Together, these effects establish GLP-1 as a central regulator of postprandial metabolism.
However, further research revealed a critical limitation: endogenous GLP-1 is rapidly degraded within a few minutes. As a result, native GLP-1 could not be used directly as a therapeutic agent.
A breakthrough emerged from an unexpected natural source. Researchers identified a peptide, exendin-4, in the saliva of the Gila monster (Heloderma suspectum). Exendin-4:
This discovery demonstrated that sustained GLP-1 receptor activation was both biologically feasible and clinically valuable. Exendin-4 subsequently served as the foundation for the first approved GLP-1 receptor agonist, bridging the gap from basic biological observation to therapeutic application.
Building on these findings, researchers developed synthetic GLP-1 receptor agonists that combined prolonged activity with reproducible pharmacological properties. By the mid-2000s, the first GLP-1-based therapies for type 2 diabetes were approved.
Subsequent clinical trials soon showed benefits beyond glycemic control:
What began as fundamental research into gut-derived hormones evolved into a new therapeutic class with broad metabolic relevance.
Today, GLP-1-based therapies are used in the treatment of both diabetes and obesity, and ongoing research is exploring their potential benefits in cardiovascular disease and other conditions. The development of GLP-1 therapeutics illustrates how long-term, curiosity-driven biological research can translate into meaningful medical innovation.
At the same time, this history highlights that such progress depends on a chain of interconnected steps: scientific discovery, experimental validation, clinical development, and the strategic protection of intellectual property. While nature may provide the initial lead structures, only systematic development and legal safeguarding allow these insights to become reliable therapies and made available to patients.
